View, Check Sucampo Pharmaceuticals Probability Of Bankruptcy. Follow My #1 Rule Instead.
The current consensus among 0 contributing investment analysts is to n/a stock in Sucampo Pharmaceuticals.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Sucampo Pharmaceuticals financial strength is of vital concern to both outside investors and internal stakeholders.
Sucampo shares are off to the races after topping Wall Street's profit expectations in the fourth-quarter.
The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.02.
), Sucampo Pharmaceuticals has received 278 “underperform” votes. Community Sentiment. If you still believe the symbol you are trying to look up is valid please. Real time Sucampo Pharmaceuticals (SCMP) stock price quote, stock graph, news & analysis. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257
View all competitors. Before it's here, it's on the Bloomberg Terminal. George Budwell, Sean Williams, and Brian Feroldi | Jun 16, 2017, Timothy Green, Sean Williams, and Daniel Miller | Oct 8, 2016. Cancel.
Need Data? Rockville, MD 20850
Sucampo's largest owners by far were its founders, Ryuji Ueno and Sachiko Kuno, who together owned a combined 30 percent of outstanding stock.
Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; Consensus Rating: N/A; Consensus Price Target: $0.00; Forecasted Upside:-100.00 %; Number of Analysts: 0; Breakdown: 0 Sell Ratings; 0 Hold Ratings; 0 Buy Ratings ; 0 Strong Buy Ratings $ 18.00 As of 02/13/2018 01:00 AM ET +0.30 … Learn more. Financials. High institutional ownership can be a signal of strong market trust in this company.
Touch device users, explore by touch or with swipe gestures. We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. With PEG ratios well below one, these small-cap value stocks could be screaming buys. ARN keeps track of all major brokerages’ stock ratings and recommendations, including Goldman
Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Percentage Held by Insiders. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Let's conquer your financial goals together...faster.
CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP). All rights reserved.
Get daily stock ideas top-performing Wall Street analysts. Based on aggregate information from My MarketBeat watchlists, some companies that other Sucampo Pharmaceuticals investors own include XOMA (XOMA), Sprint (S), Alnylam Pharmaceuticals (ALNY), Teekay Tankers (TNK), Xenon Pharmaceuticals (XENE), Gilead Sciences (GILD), Opko Health (OPK), Cisco Systems (CSCO), Infinera (INFN) and Micron Technology (MU).
+((!++(!!)+!!+!!+!!+!!+!!+!!+!!+)+(!++(!!)-)+(!+-(!!))+(!++(!!)+!!+!!)+(+!!)+(!++(!!)+!!+!!+!!+!!+!!+!!+!!)+(!++(!!)+!!+!!+!!+!!+!!+!!)+(!++(!!)-)+(!++(!!)+!!))/+((!++(!!)+!!+!!+!!+!!+!!+)+(!++(!!)+!!+!!)+(!++(!!)+!!+!!+!!+!!+!!+!!)+(!++(!!)+!!+!!+!!)+(!++(!!)+!!+!!)+(!++(!!)+!!+!!)+(!++(!!)+!!+!!+!!+!!)+(+!!)+(!+-(!! RESCULA is a Big Potassium channel activator used to lower intraocular pressure. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. Suite 550
Please enable Cookies and reload the page.
Sucampo's 8-K filing with the SEC delivers a nice surprise to shareholders.
He’s agreed to share his secret with a small group of investors. 67.09% of the stock of Sucampo Pharmaceuticals is held by institutions. Vote “Underperform” if you believe SCMP will underperform the S&P 500 over the long term. AT&T Hampered by Setbacks, But Could be a Breakout Play, The Coca-Cola Company (NYSE:KO) Is A Buy For Dividend-Growth Investors, CSX Corporation (NASDAQ:CSX) Is Another Reason To Bet On Transportation, PayPal (NASDAQ: PYPL) Hits All Time Highs And Wants More, The Stars are Aligned for Growth at Align Technology (NASDAQ:ALGN), Workhorse Group (NASDAQ:WKHS) Could Be The Tesla Of Delivery Vehicles, Getting in on AutoNation (NYSE:AN) a Smart Move, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, 8 Stocks That Robinhood Investors Got Right, 7 Stocks That Will Help You Forget About the Fed, 7 Stocks That Don’t Care Who Wins the Election, 7 Semiconductor Stocks to Power Your Portfolio, Receive Analysts' Upgrades and Downgrades Daily.
Please verify the symbol is currently traded on NMS Exchange.
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API. The Company is focused on the development and commercialization of pharmaceutical products.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) announced its quarterly earnings data on Wednesday, November, 1st. Can Winnebego (NYSE:WGO) Recover From The Post-Earings Blues?
You don’t have to be one of them. Stock analysis for Sucampo Pharmaceuticals Inc (SCMP) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
See what's happening in the market right now with MarketBeat's real-time news feed. Leverage. Efficiency and cost control are keys to Sucampo Pharmaceuticals success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. …
Most Options traders lose 7 out of 10 trades. No pricing data is available for this time frame, Novavax, Inc.: Novavax Expands Executive Leadership and Announces Key Promotions, Novavax Expands Executive Leadership and Announces Key Promotions, Novavax Announces Additions to Executive Leadership, Novavax, Inc.: Novavax Announces Additions to Executive Leadership, Aurinia Appoints Joe Miller as Chief Financial Officer, Numab and Eisai Enter Into a Global Research and Option Agreement to Discover and Develop Multi-Specific Antibody, Milestone Pharmaceuticals Appoints Paul Edick Chairman of its Board of Directors, BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business. This process is automatic.
It employs 1 people..
Real-time trade and investing ideas on Sucampo Pharmaceuticals, Inc. SCMP from the largest community of traders and investors.
(Add your “underperform” vote.)
Looking for new stock ideas? )). Get New Sucampo Pharmaceuticals Analyst Ratings Delivered To Your Inbox.
View which stocks are hot on social media with MarketBeat's trending stocks report. Trending now.
company data provided by Morningstar and Zacks Investment Research.
Summary; Fundamentals; Profile. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. "document.write('
'); Sign-up to receive the latest news and ratings for SCMP and its competitors with MarketBeat's FREE daily newsletter.
Sucampo Pharmaceuticals has received 51.99% “outperform” votes from our community. View our full suite of financial calendars and market data tables, all for free. Apparently, Sucampo Pharmaceuticals is not available for investing at the moment. The potential to double always comes with risk, but these stocks could give investors incredible returns. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation.
(Add your “outperform” vote. The average price target represents a -100.00% upside from the last price of $18.00.
"Bank of America… Wells Fargo… U.S. Bank…Citibank… Chase? (Add your “underperform” vote.).
VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease.
Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Your current horizon is 30 days -. © American Consumer News, LLC dba MarketBeat® 2010-2020. sell any security.